Spironolactone and Dexamethasone in Patients Hospitalized With COVID-19
Status:
Recruiting
Trial end date:
2021-09-02
Target enrollment:
Participant gender:
Summary
The Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) is a rapidly spreading
infection of the respiratory tract. Most infected patients have either asymptomatic disease
or mild symptoms. However, a proportion of patients, especially elderly men or patients with
comorbidities, are at risk of developing acute respiratory distress syndrome (ARDS). ARDS,
alongside clotting abnormalities, is known to be a major contributor to SARS-CoV-2-related
mortality and admission to intensive care units, with evidenced effective preventative
treatment options lacking. In this study, the investigators test a novel hypothesis that the
use of a combination of spironolactone and dexamethasone at low doses will improve the
clinical progression of the infection evaluated by the 6-point ordinal scale in patients with
moderate and severe disease by blocking exocytosis of the Weibel-Palade bodies from
endothelial cells.